APOE and neoplasm: The LXR/ApoE axis influences MDSC survival, and LXR agonists (RGX-104/GW3965) have demonstrated efficacy in mouse models, significantly reducing tumor growth and metastasis by inducing MDSC apoptosis (66–68).